Peptide Comparison
Retatrutide vs Orforglipron
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Orforglipron has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Retatrutide | Orforglipron | |
|---|---|---|
| Class | GIP/GLP-1/glucagon triple agonist | Oral non-peptide GLP-1 agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects | Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14] |
| Route | SC injection | Oral |
| Half-life | ~6 days | ~29-49 hrs |
| Dosage (research) | 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) | 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15] |
| Evidence tier | Phase 3 | FDA-Approved |
| Research depth | 217 indexed | 197 indexed |
| Availability | Investigational | Prescription |
| Reported risks | GI side effects; Phase 3 ongoing; long-term safety unknown | GI effects; hepatic enzyme elevations |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Retatrutide or Orforglipron?
Orforglipron has stronger documented evidence (FDA-Approved) than Retatrutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. Retatrutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Retatrutide and Orforglipron?
Retatrutide is classed as GIP/GLP-1/glucagon triple agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Retatrutide, ~6 days; Orforglipron, ~29-49 hrs. Routes in published studies: Retatrutide, SC injection; Orforglipron, Oral.
Which has stronger evidence, Retatrutide or Orforglipron?
Orforglipron has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies. Orforglipron is graded FDA-Approved, with 38 cited sources on its reference page and 197 indexed studies.
Which is more accessible, Retatrutide or Orforglipron?
Orforglipron is FDA-approved and Retatrutide is not. Catalog status: Retatrutide, Investigational; Orforglipron, Prescription.
Are Retatrutide and Orforglipron ever combined?
Retatrutide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…